The nonprofit is focused on access to precision medicine testing and treatment for former special operations forces personnel ...
MD Anderson Researchers Secure Grant to Test Cell Therapy in Melanoma Patients With Brain Metastasis
With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR ...
Doctors can use the test, developed by Endeavor Health in collaboration with GenomicMD, to direct more aggressive treatment ...
From 2017 until Oct. 1, 2025, sponsors have submitted around 50 INDs seeking to begin clinical testing of individualized ...
The FDA recently removed non-ambulatory Duchenne patients from the gene therapy's indication, which Sarepta hopes to have reinstated.
The British company's CAR T-cell therapy will now be available through the National Health Service in England and Wales.
NEW YORK – Fifteen drugs will be offered at a lower cost under Medicare Part D beginning in 2027 after the latest round of drug price negotiations between pharma companies and the Centers for Medicare ...
Itvisma has the same active ingredient as Novartis' Zolgensma, but is approved for a broader population of older patients with an intrathecal formulation.
The firm plans to submit results from the Phase III OptiTROP-Lung05 trial to regulators in China, seeking approval for sac-TMT and Keytruda in PD-L1-positive patients.
The CAP committee recommended that pathologists use mass spectrometry to determine the subtype for amyloidosis patients being considered for treatment.
NEW YORK – Tempus AI has scooped up the pharmacogenetics assets held by OneOme, a company that recently went out of business due to financial difficulties.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback